HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China Healthcare Weekly (Feb.19) - VBP on Biosimilar Drugs, Poor Performance of Healthcare Sector

Jinxin Fertility (1951.HK) - The New Policy, the Logic and the Risk Factors

Lepu Medical Technology A (300003 CH) - Does Not Have High Moat

Pre-IPO Joinn Laboratories - The Future Performance Is Worth Looking Forward To

Pre-IPO BeiGene - Would the IPO on the STAR Market Be the Last Hurrah?

Pre-IPO Betta Pharmaceuticals - Insights on Products and Concerns

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Bottom-Up

Innovent Biologics Inc / Equity Bottom-Up

<p>In recent years, <a href="https://www.smartkarma.com/entities/innovent-biologics-inc" target="_blank" data-smartkarma-citation="entities:27452:1" rel="noopener">Innovent Biologics Inc (1801 HK)</a> has launched a number of successful products, and the Company's investment value has significantly increased. Innovent leads the domestic counterparts in the layout of biological drugs and adhere to the development of internationally competitive products. The Company also establishes an excellent team to ensure the efficient implementation of the strategy. Meanwhile, Innovent is gradually transforming from a biotech company to a big pharma. With dozens of products in the pipeline, the Company is focusing on mainstream areas and is in the first echelon of clinical progress. In addition, with the rapid increase of sales after the listing of PD-1, its commercialization capability has also been recognized by the market. </p>

In recent years, Innovent Biologics Inc (1801 HK) has launched a number of successful products, and the Company's investment value has significantly increased. Innovent leads the domestic counterparts in the layout of biological drugs and adhere to the development of internationally competitive products. The Company also establishes an excellent team to ensure the efficient implementation of the strategy. Meanwhile, Innovent is gradually transforming from a biotech company to a big pharma. With dozens of products in the pipeline, the Company is focusing on mainstream areas and is in the first echelon of clinical progress. In addition, with the rapid increase of sales after the listing of PD-1, its commercialization capability has also been recognized by the market. 

Hualan Biological Engineering (002007 CH)

Shenzhen Salubris Pharmaceuticals A (002294 CH)

Zhejiang Hisun Pharmaceutical Co, Ltd. (600267 CH)

Chengdu Kanghong Pharmaceutical Group-A (002773 CH)

Innovent Biologics (1801 HK) - Have the Genes to Become a Big Pharma